Karyopharm Therapeutics's GAAP loss for 2021 was $124.088 million, down 36.8% from $196.273 million in the previous year. Revenue increased 94.1% to $209.819 million from $108.085 million a year earlier.
Karyopharm Therapeutics's GAAP loss for 2021 was $124.088 million, down 36.8% from $196.273 million in the previous year. Revenue increased 94.1% to $209.819 million from $108.085 million a year earlier. 
investors.karyopharm.com
English (US) 